{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:33:30Z","timestamp":1787956410674,"version":"build-2784847793"},"reference-count":23,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hypomethylating agents are the most widely used upfront therapy for patients with myelodysplastic syndrome (MDS) who are not suitable for hematopoietic stem cell transplantation. In Australia, azacitidine was, until recently, the only approved and subsidized treatment for patients with intermediate\u20102 and high\u2010risk MDS, chronic myelomonocytic leukemia, and low blast acute myeloid leukemia. We analyzed prescription data to evaluate the real\u2010world persistence and overall survival (OS) of patients prescribed azacitidine for the first time in Australia. A retrospective cohort analysis of patients who had been prescribed Pharmaceutical Benefits Scheme (PBS)\u2010listed azacitidine for the first time, between January 2016 and April 2021, was conducted using the PBS 10% dataset. Treatment persistence and OS were estimated using Kaplan\u2013Meier methods. The impact of the number of treatment cycles and treatment adherence on OS was also estimated. There were 351 patients in the PBS 10% dataset who initiated treatment with azacitidine. The average age (standard deviation [SD]) at azacitidine initiation was 71.9 (11.1) years and the average number (SD) of azacitidine prescriptions was 5.6 (0.2). The median persistence on azacitidine was 15.6 months, and the OS was 13.4 months. The median OS for patients who had six or more cycles of azacitidine treatment was greater compared to patients who had five or less cycles of treatment. The data from this real\u2010world study illustrate the unmet medical needs of patients with MDS treated with azacitidine in Australia. The majority of patients are not treated with the optimal number of cycles of azacitidine, which is negatively correlated with patient outcomes.<\/jats:p>","DOI":"10.1002\/jha2.911","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T12:39:26Z","timestamp":1715949566000},"page":"527-534","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real\u2010world study of the use of azacitidine in myelodysplasia in Australia"],"prefix":"10.1002","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8069-090X","authenticated-orcid":false,"given":"Anoop","family":"Enjeti","sequence":"first","affiliation":[{"name":"Faculty of Medicine and Public Health University of Newcastle  Newcastle New South Wales Australia"},{"name":"Department of Haematology Calvary Mater Hospital  Newcastle New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Ashraf","sequence":"additional","affiliation":[{"name":"Department of Haematology Calvary Mater Hospital  Newcastle New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Caillet","sequence":"additional","affiliation":[{"name":"Prospection Pty Ltd.  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arif","family":"Alam","sequence":"additional","affiliation":[{"name":"Prospection Pty Ltd.  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Silar","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Public Health University of Newcastle  Newcastle New South Wales Australia"},{"name":"Department of Haematology Calvary Mater Hospital  Newcastle New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold","family":"Keer","sequence":"additional","affiliation":[{"name":"Astex Pharmaceuticals, Inc.  Pleasanton California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Castaldi","sequence":"additional","affiliation":[{"name":"Otsuka Australia Pharmaceutical  Chatswood New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taleisha","family":"Paine","sequence":"additional","affiliation":[{"name":"Otsuka Australia Pharmaceutical  Chatswood New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,5,17]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0085-4"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.6.2079"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-420489"},{"issue":"3","key":"e_1_2_13_5_1","first-page":"545","article-title":"Allogeneic stem cell transplantation for MDS","volume":"2","author":"Villar S","year":"2021","journal-title":"Hematology"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620720955006"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01831-1"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70003-8"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007334"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124878"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-289280"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15273"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14305"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-015-1616-8"},{"issue":"4","key":"e_1_2_13_15_1","article-title":"Using Australian Pharmaceutical Benefits Scheme data for pharmacoepidemiological research: challenges and approaches","volume":"25","author":"Page E","year":"2015","journal-title":"Public Health Res Pract"},{"key":"e_1_2_13_16_1","unstructured":"Prospection. Available from:https:\/\/www.prospection.com"},{"key":"e_1_2_13_17_1","unstructured":"Teva Pharma Australia Pty Ltd. Australian PI\u2014Azacitidine\u2010TEVA\u00ae (Azacitidine) Powder for Injection.2022. Available from:https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP\u20102019\u2010PI\u201001741\u20101&d=20210917172310101"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.2598.2598"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.1287.1287"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0936"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2015.03.006"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12079"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.283"},{"key":"e_1_2_13_24_1","unstructured":"Australian Institute of Health and Welfare.Cancer data in Australia.2021."}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.911","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T15:40:56Z","timestamp":1724168456000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,17]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1002\/jha2.911"],"URL":"https:\/\/doi.org\/10.1002\/jha2.911","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,17]]},"assertion":[{"value":"2023-12-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}